Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
about
Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover studyItopride therapy for functional dyspepsia: a meta-analysisDrug induced QT prolongation and torsades de pointesDrug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsAdverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature reviewAnalysis of aspirin-associated risks in healthy individualsReview article: the management of heartburn in pregnancyThe tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarctionThe effect of moxifloxacin on QTc and implications for the design of thorough QT studies.ECG-ViEW II, a freely accessible electrocardiogram database.Drug-induced QT interval prolongation: mechanisms and clinical managementPrucalopride for constipation.Drug treatment of non-motor symptoms in Parkinson's disease.Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block.Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast).Drug-drug interactions in pharmacologic management of gastroparesis.Chinese herbal medicine liu jun zi tang and xiang sha liu jun zi tang for functional dyspepsia: meta-analysis of randomized controlled trialsTorsades de pointes associated with voriconazole use.Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.Adverse drug event monitoring at the Food and Drug Administration.Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.Chronic metoclopramide therapy for diabetic gastroparesis.Pharmacogenetics in drug regulation: promise, potential and pitfalls.Clinical relevance and management of drug-related QT interval prolongation.Effect of oral erythromycin on gastric and small bowel transit time of capsule endoscopyEffect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.Cough. 3: chronic cough and gastro-oesophageal refluxThe Pharmacological Effects of Benachio-F(®) on Rat Gastrointestinal FunctionsDrug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).Gastric emptying and symptoms of bulimia nervosa: effect of a prokinetic agent.Review article: diagnosis and management of night-time reflux.Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants.Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Pharmacogenomics and acquired long QT syndrome.Improving postapproval drug safety surveillance: getting better information soonerEffective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis.Pharmacogenetic issues in thorough QT trials.Can pharmacogenetics help rescue drugs withdrawn from the market?Increase in mortality rate following coprescription of cisapride and contraindicated drugs.
P2860
Q24608623-37A1F2A7-59DD-411E-BEBA-A24C0AEAD9D5Q24633164-1B6B08C0-1DBD-4A94-A3C5-5890CADCFEA2Q24673854-3F6F2F1F-4023-42A9-99AC-65CE5C3ADB30Q27006580-DE0D38C0-AFF2-43E5-AA62-9141636A7C17Q28071256-424C4099-ED2B-4CB0-9223-2FAF56FA7D54Q28082238-0B7DBE29-1B14-491E-83ED-DA093F31ACDBQ28211608-B718B21C-9AAE-4F8B-969A-C8881CDD2302Q28277056-9D3A27EF-47CB-46E7-92F0-EDF70F2DE9B4Q33297001-534F4000-E32D-4B1E-A06F-8E7694BE4054Q33411837-FF6AC800-0FDD-448C-BD97-01D7B17FC462Q33596588-DBD1301A-DACE-466E-8F32-54AF7907112EQ33949538-313034C6-544D-402D-9F8B-3C9249B976B0Q34094831-CA1AC9D9-A82D-4EA3-8A31-014B214E04A4Q34122222-9ED2E362-6673-4243-8D95-FA3AE9C6A4C3Q34134389-9C91BC82-4E40-4D50-B495-0CAE0DA72E49Q34377528-AEF0872E-A206-4A50-B9AF-0FB539B434CBQ34480053-D57504A9-85A5-40D7-920B-666CD3E70101Q34543408-252D5505-3041-4B5C-AD93-14B22F450E0FQ34576005-3E79F81E-404F-4650-8887-764D342173C9Q34711627-9C1F4ADE-75BE-41E8-BA1B-001F4A95C202Q34740872-EEBD48EA-F4CE-40AE-910A-3EA94591F1D2Q35026383-B8797D6E-2079-4BE5-85A3-2FF10F2AF959Q35035103-F1857635-C371-4108-800A-CC1E9974C03CQ35038052-F508FE60-9768-4D5E-89CA-46D134D73D51Q35186542-BA42D931-213B-4C7A-854B-3F64FBFE4BB4Q35435788-D13D62E1-B147-4625-BAEE-6F9B5E57F7CDQ35595527-71DC38E3-0867-4A61-9317-0FDE0D259ADEQ35596590-EB92A4E1-F03C-4692-9A13-40EF37120129Q35811478-6D6B6812-1C22-40AB-9154-7C79901916ACQ35826495-D79A032A-8925-4BCD-A7C1-9E7EBD1AE1F1Q35857075-DF17E22C-2A2D-4736-804B-7C56E4C125DFQ35939808-289A4B99-ADE1-45D1-9D41-A7AB5AABD89CQ36005912-045AB004-3949-4017-984D-EDA0BFAA7AF1Q36040772-58F0729A-F41D-43B3-A51F-2ABD425853B1Q36192679-E4ADEB0B-4D82-4BB1-BC60-A3857C2D7286Q36367834-918BDBA2-CA73-49CF-AC86-2EA016E8D612Q36426025-0F7378A4-E8CE-4236-B9F5-51261938397CQ36505465-CE410495-7B36-4CF6-B529-B9B4C8D2E95FQ36596713-AC38C50C-1976-46E3-A2CC-55FF1A4BAFB8Q36765263-D65B6B13-32CD-4D70-AA10-4B1512867623
P2860
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Postmarketing reports of QT pr ...... nistration regulatory actions.
@en
Postmarketing reports of QT pr ...... nistration regulatory actions.
@nl
type
label
Postmarketing reports of QT pr ...... nistration regulatory actions.
@en
Postmarketing reports of QT pr ...... nistration regulatory actions.
@nl
prefLabel
Postmarketing reports of QT pr ...... nistration regulatory actions.
@en
Postmarketing reports of QT pr ...... nistration regulatory actions.
@nl
P2093
P2860
P1476
Postmarketing reports of QT pr ...... nistration regulatory actions.
@en
P2093
Gallo-Torres H
Rodriguez EM
Talarico L
Wysowski DK
P2860
P304
P356
10.1111/J.1572-0241.2001.03927.X
P407
P577
2001-06-01T00:00:00Z